NHS trusts retreat from Palantir tools

The Federated Data Platform (FDP) used by NHS England is structured as a £330 million contract with Palantir, and has become a focal point of debate over how patient data is handled and how digital tools shape care delivery. Coverage dated 2 October 2026 highlights that scrutiny of the programme has accelerated, with questions over its long‑term role in the health service.

On the same date, a news report said that more than 44,000 people have submitted legal objections aimed at preventing their records from being used on the Palantir‑powered platform. These objections add a legal dimension to the policy and operational challenges already surrounding the FDP.

Professional concerns are also explicit. The British Medical Association has urged doctors not to use the FDP platform, signaling unease among clinicians about the system’s deployment and its implications for clinical practice.

While opposition has grown, other reporting on 2 October 2026 cites data attributed to Palantir or to NHS analyses that present a more positive performance picture. These sources report around 117,000 additional procedures associated with the platform’s use.

The same coverage points to specific operational metrics, including a 14.3% reduction in long‑stay discharge delays and a 5.6% improvement in 28‑day cancer diagnosis rates. These figures are presented as outcomes linked to use of the Federated Data Platform, though they sit alongside ongoing questions about data governance and consent.

Accounts of how widely the FDP is deployed differ, with reports noting that there is no single, consistent view of adoption across NHS trusts. This mix of positive performance indicators and fragmented deployment information contributes to an unsettled picture of the platform’s current impact.

Against this backdrop, new analysis shows that more than 20 NHS trusts have stopped using Palantir’s waiting‑list tools. This indicates that, in some parts of the system, earlier deployments of Palantir technology are being reversed or scaled back.

The discontinuation of these waiting‑list tools comes as the wider FDP contract remains active, illustrating a divergence between national‑level commitments and local implementation choices. For Palantir, this pattern signals uneven acceptance of its products within the NHS estate.

Taken together with rising legal objections and professional guidance against FDP use, the move by over 20 trusts to drop waiting‑list tools underscores the challenges to sustaining and expanding the company’s footprint in NHS operational systems.

The combination of a £330 million contract value, contested performance narratives, and active resistance from both patients and clinicians places the Federated Data Platform at the centre of the NHS digital strategy debate. Legal objections above 44,000 and calls from the British Medical Association to avoid the system suggest continuing headwinds.

At the same time, the performance metrics attributed to the platform, including additional procedures and improvements in discharge and cancer diagnosis measures, will remain key reference points for advocates of the FDP. The contrast between these metrics and the withdrawal of waiting‑list tools by more than 20 trusts highlights the tension between national ambitions and local confidence.

With conflicting data on impact and varying levels of adoption across trusts, the future configuration and scale of Palantir’s role in NHS data infrastructure remains uncertain. How these forces resolve will shape both patient data use and operational decision‑making in the health service.